Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106719557> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W3106719557 abstract "Abstract Background The inflammatory response after aneurysmal subarachnoid haemorrhage (aSAH) has been associated with early brain injury, delayed cerebral ischaemia, poor functional outcome, and case fatality. In experimental SAH studies, complement C5 antibodies administered shortly after SAH reduced brain injury with approximately 40%. Complement component C5 may be a new therapeutic target to reduce brain injury and hereby improve the outcome after aSAH. We aim to investigate the pharmacodynamic efficacy and safety of eculizumab (complement C5 antibody) in patients with aSAH. Methods A randomised, controlled, open-label, phase II clinical trial with blinded outcome assessment. Eculizumab (1200 mg) is administered intravenously < 12 h, on day 3 and on day 7 after ictus. Patients in the intervention group receive prophylactic antibiotics for 4 weeks, and those with a central line or an external ventricular shunt and a positive fungal or yeast culture also receive prophylactic antifungal therapy for 4 weeks. The primary outcome is C5a concentration in the cerebrospinal fluid (CSF) on day 3 after ictus. Secondary outcomes include the occurrence of adverse events, inflammatory parameters in the blood and CSF, cerebral infarction on magnetic resonance imaging, and clinical and cognitive outcomes. We aim to evaluate 26 patients with CSF assessments, 13 in the intervention group and 13 in the comparator group. To compensate for early case fatality and inability to obtain CSF, we will include 20 patients per group. Discussion The CLASH trial is the first trial to investigate the pharmacodynamic efficacy and safety of eculizumab in the early phase after aSAH. Trial registration Netherlands Trial Register NTR6752 . Registered on 27 October 2017 European Clinical Trials Database (EudraCT) 2017-004307-51" @default.
- W3106719557 created "2020-12-07" @default.
- W3106719557 creator A5019984978 @default.
- W3106719557 creator A5039831229 @default.
- W3106719557 creator A5048148496 @default.
- W3106719557 date "2020-11-25" @default.
- W3106719557 modified "2023-10-15" @default.
- W3106719557 title "CompLement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Haemorrhage (CLASH): study protocol for a randomised controlled phase II clinical trial" @default.
- W3106719557 cites W1583938359 @default.
- W3106719557 cites W2007556864 @default.
- W3106719557 cites W2008977904 @default.
- W3106719557 cites W2039885590 @default.
- W3106719557 cites W2067892766 @default.
- W3106719557 cites W2111062482 @default.
- W3106719557 cites W2128973824 @default.
- W3106719557 cites W2137299577 @default.
- W3106719557 cites W2153070776 @default.
- W3106719557 cites W2159911182 @default.
- W3106719557 cites W2161525412 @default.
- W3106719557 cites W2331901704 @default.
- W3106719557 cites W2477048823 @default.
- W3106719557 cites W2765810957 @default.
- W3106719557 cites W2983425799 @default.
- W3106719557 cites W2991780303 @default.
- W3106719557 doi "https://doi.org/10.1186/s13063-020-04838-6" @default.
- W3106719557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7687754" @default.
- W3106719557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33239044" @default.
- W3106719557 hasPublicationYear "2020" @default.
- W3106719557 type Work @default.
- W3106719557 sameAs 3106719557 @default.
- W3106719557 citedByCount "5" @default.
- W3106719557 countsByYear W31067195572022 @default.
- W3106719557 countsByYear W31067195572023 @default.
- W3106719557 crossrefType "journal-article" @default.
- W3106719557 hasAuthorship W3106719557A5019984978 @default.
- W3106719557 hasAuthorship W3106719557A5039831229 @default.
- W3106719557 hasAuthorship W3106719557A5048148496 @default.
- W3106719557 hasBestOaLocation W31067195571 @default.
- W3106719557 hasConcept C111684460 @default.
- W3106719557 hasConcept C126322002 @default.
- W3106719557 hasConcept C159654299 @default.
- W3106719557 hasConcept C203014093 @default.
- W3106719557 hasConcept C2777736543 @default.
- W3106719557 hasConcept C2777991916 @default.
- W3106719557 hasConcept C42219234 @default.
- W3106719557 hasConcept C535046627 @default.
- W3106719557 hasConcept C71924100 @default.
- W3106719557 hasConceptScore W3106719557C111684460 @default.
- W3106719557 hasConceptScore W3106719557C126322002 @default.
- W3106719557 hasConceptScore W3106719557C159654299 @default.
- W3106719557 hasConceptScore W3106719557C203014093 @default.
- W3106719557 hasConceptScore W3106719557C2777736543 @default.
- W3106719557 hasConceptScore W3106719557C2777991916 @default.
- W3106719557 hasConceptScore W3106719557C42219234 @default.
- W3106719557 hasConceptScore W3106719557C535046627 @default.
- W3106719557 hasConceptScore W3106719557C71924100 @default.
- W3106719557 hasFunder F4320309052 @default.
- W3106719557 hasFunder F4320321007 @default.
- W3106719557 hasFunder F4320325060 @default.
- W3106719557 hasIssue "1" @default.
- W3106719557 hasLocation W31067195571 @default.
- W3106719557 hasLocation W31067195572 @default.
- W3106719557 hasLocation W31067195573 @default.
- W3106719557 hasLocation W31067195574 @default.
- W3106719557 hasOpenAccess W3106719557 @default.
- W3106719557 hasPrimaryLocation W31067195571 @default.
- W3106719557 hasRelatedWork W2005235612 @default.
- W3106719557 hasRelatedWork W2021690019 @default.
- W3106719557 hasRelatedWork W2027228365 @default.
- W3106719557 hasRelatedWork W2051657967 @default.
- W3106719557 hasRelatedWork W2104534610 @default.
- W3106719557 hasRelatedWork W2171068466 @default.
- W3106719557 hasRelatedWork W2209557348 @default.
- W3106719557 hasRelatedWork W2518824985 @default.
- W3106719557 hasRelatedWork W2589002500 @default.
- W3106719557 hasRelatedWork W3014578203 @default.
- W3106719557 hasVolume "21" @default.
- W3106719557 isParatext "false" @default.
- W3106719557 isRetracted "false" @default.
- W3106719557 magId "3106719557" @default.
- W3106719557 workType "article" @default.